Patients received the FlexPen if they were randomized to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin aspart) or the combination of 70% insulin aspart ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. First ...

The table is intended for use as a guide when medications labeled for refrigerated storage are inadvertently exposed to room-temperature. This may occur during routine excursions, power outages ...

The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and ...

Short-Acting Insulin (Insulin Regular) Onset: 20 minutes Peak: 2–4 hours Duration: 6–8 hours Rapid-Acting Insulin (Lispro, Aspart, FiAsp) Onset: Within 5 minutes Peak: 1–2 hours Duration: 4 ...

Phase 2b OPTI-2 trial to assess liver-targeted insulin's ability to reduce hypoglycemia and improve postprandial control using Dexcom G7 CGM data< ...

The insulin pens market is witnessing significant growth due to the increasing prevalence of diabetes worldwide and the rising preference for advanced, user-friendly insulin delivery systems. Insulin ...

The United States insulin pen market size was valued at USD 4.2 billion in 2024 and is projected to hit around USD 8.1 billion by 2033, growing at a CAGR of 6.9% during the forecast period 2025 to ...

The U.S. insulin pen market is set to grow from USD 4.2 billion in 2024 to USD 8.1 billion by 2033 at a 6.9% CAGR. Key growth drivers include advanced technology, increased awareness, and favorable ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...